| ID | Type | Description | Link |
|---|---|---|---|
| UG3DA054825 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Altasciences Company Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This is a Phase 1, single-centre, randomized, double-blind, placebo-controlled, multiple ascending doses (MAD) study in healthy male and female adult participants.
The study will include up to 48 participants (12 participants per cohort) who will be randomized 9:3 to active drug or placebo. Each cohort will receive AZD4041 or placebo in a MAD study.
A sequential cohort MAD design will be employed to assure that higher doses are administered to healthy participants only after lower doses have demonstrated an acceptable safety profile.
The total study duration will be up to 59 days (including Screening) per participant.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1: AZD4041 Dose Level 1 | Experimental | Participants will receive oral solution of AZD4041 dose level 1 once daily (QD) directly into the mouth using a syringe from Days 1 to 14. |
|
| Cohort 2: AZD4041 Dose Level 2 | Experimental | Participants will receive oral solution of AZD4041 dose level 2 QD directly into the mouth using a syringe from Days 1 to 14. |
|
| Cohort 3: AZD4041 Dose Level 3 | Experimental | Participants will receive oral solution of AZD4041 dose level 3 QD directly into the mouth using a syringe from Days 1 to 14. |
|
| Cohorts 1-3: Pooled Placebo | Placebo Comparator | Participants will receive oral solution of placebo equivalent to AZD4041 volume QD directly into the mouth using a syringe from Days 1 to 14. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD4041 | Drug | Participants will receive oral solution of AZD4041 as stated in arm description. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. | From Day 1 to Day 31 |
| Number of Participants With Abnormal Vital Signs Reported as TEAEs | Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal finding in the vital sign parameters (blood pressure, pulse rate, and body temperature). | From Day 1 to Day 31 |
| Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs | Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported. Abnormal clinical laboratory parameters defined as any abnormal finding during analysis of general biochemistry, hematology, and urinalysis. | From Day 1 to Day 31 |
| Number of Participants With Abnormal Electrocardiograms (ECGs) Reported as TEAEs | Number of participants with abnormal ECGs reported as TEAEs are reported. | From Day 1 to Day 31 |
| Number of Participants With Suicidal Ideation or Behavior Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of AZD4041 After Day 1 Dose | The Cmax of AZD4041 after Day 1 dose is reported. | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose |
| Maximum Observed Plasma Concentration (Cmax) of AZD4041 After Day 14 Dose |
Not provided
Inclusion Criteria
Provision of signed and dated written informed consent form prior to any study specific procedures
Stated willingness to comply with all study procedures and availability for the duration of the study
Healthy adult male or female participants. Female participants must be of non-childbearing potential (postmenopausal and/or surgically sterile)
If female, meets one of the following criteria:
Physiological postmenopausal status, defined as the following:
Surgical sterile, defined as those who have had:
hysterectomy, bilateral oophorectomy and/or bilateral salpingectomy, or bilateral tubal ligation. Women who are surgically sterile must provide documentation of the procedure by an operative report, ultrasound, or other verifiable documentation; and must have a negative pregnancy test result at screening and check-in.
If postmenopausal and has an FSH of < 40 mIU/mL, but meets all other criteria in (1) or (2) above as well as all the other inclusion criteria, screening oestradiol serum level must be equal to or below 150 pmol/L.
Exclusion Criteria
Female who is lactating
Female who is pregnant according to the pregnancy test at Screening or prior to the first study drug administration
Male participants with a history of oligospermia or azoospermia or any other disorder of the reproductive system
Male participants who are undergoing treatment or evaluation for infertility.
History of significant allergy/ hypersensitivity to AZD4041 or products related to AZD4041 as well as severe allergy/hypersensitivity reactions (like angioedema) to any drugs
Presence or history of significant gastrointestinal, liver or kidney disease, or any other condition that is known to interfere with drug absorption, distribution, metabolism, or excretion, or known to potentiate or predispose to undesired effects
History of any significant disease, including [but not necessarily limited to] significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic, or dermatologic disease
Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (> 21 units/week or > 3 units/day for men; > 14 units/week or > 2 units/day for women; intake of excessive alcohol, acute or chronic)
History of any significant psychiatric disorder according to the criteria of the Diagnostic and Statistical manual of Mental Disorders, 5th Edition (DSM-5, American Psychiatric Association 2013) which, in the opinion of the Investigator, could be detrimental to participant safety or could compromise study data interpretation.
History of substance use disorder, other than nicotine or caffeine (as per DSM-5 criteria)
Use of any prescription drugs, including hormone replacement therapy in the 28 days prior to the first study drug administration, that in the opinion of an Investigator would put into question the status of the participant as healthy
Use of St. John's wort in the 28 days prior to the first study drug administration
Positive test result for alcohol and/or drugs of abuse at Screening or prior to the first study drug administration
Any clinically significant illness, medical/surgical procedure or trauma within the 28 days prior to the first study drug administration
Any abnormal or clinically significant findings in laboratory test results at Screening that would, in the opinion of an Investigator, increase the participant's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data
Positive screening results to human immunodeficiency virus (HIV) antigen/antibody (Ag/Ab) combo, hepatitis B surface antigen, or hepatitis C virus tests
Showing suicidal tendency as per the C-SSRS questionnaire administered at Screening
Any abnormal vital signs, after 10 minutes supine rest, as defined in the list below, at the Screening Visit/or Day -2 Out of range tests may be repeated once for each visit at the discretion of an Investigator.
Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG and any clinically important abnormalities in the 12-lead ECG which, in an Investigator's opinion, may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology, particularly in the protocol-defined primary lead or left ventricular hypertrophy at Screening or prior to the first study drug administration
Prolonged QT interval corrected for HR using Fridericia's formula (QTcF) > 440 ms at Screening or prior to the first study drug administration
Shortened QTcF < 340 ms at Screening or prior to first study drug administration
Known family history of long QT syndrome
ECG interval measured from the onset of the P wave to the onset of the complex between Q and S waves (QRS complex) (PR [PQ]) interval shortening < 120 ms (PR > 110 ms but < 120 ms is acceptable if there is no evidence of ventricular preexcitation) at Screening or prior to the first study drug administration
PR (PQ) interval prolongation (> 220 ms), persistent or intermittent second (Wenckebach block while asleep is not exclusive), or third degree atrioventricular (AV) block, or AV dissociation at Screening or prior to the first study drug administration
Persistent or intermittent complete bundle branch block, incomplete bundle branch block, or intraventricular conduction delay (IVCD) with ECG interval measured from the onset of the QRS complex to the J point (QRS) > 110 ms. Participants with QRS > 110 ms but < 115 ms are acceptable if there is no evidence of ventricular hypertrophy or preexcitation at Screening or prior to the first study drug administration
In the pre-dose 24 hour telemetry, presence of ≥ 10 ventricular premature contractions (VPCs) during 1 hour, or ≥ 100 VPCs during 24-hours of telemetry, or any occurrence of paired VPC (ventricular couplets) or other repetitive ventricular rhythms, including non-sustained or sustained (> 30 second duration), slow (< 100 bpm), or fast (≥ 100 bpm) ventricular tachycardias.
Vaccination with the Coronavirus disease 2019 (COVID-19) vaccine less than 14 days prior to first study dose administration
Scheduled immunization with a COVID-19 vaccine (first or second dose) during the study that, in the opinion of an Investigator, could potentially interfere with participant participation, participant safety, study results, or any other reason
Use of any prescribed or nonprescribed oral and topical inhibitors/inducers of CYP3A4 (including shampoo).
Excessive intake of caffeine-containing drinks or food (eg, coffee, tea, chocolate) as judged by an Investigator
Participants who have previously received AZD4041
Any history of tuberculosis
Involvement of any AstraZeneca or study site employee or their close relatives
Judgment by an Investigator that the participant should not participate in the study if they have any ongoing or recent (ie, during the Screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements
Presence of any tongue piercings or history of any tongue piercings in the last 90 days prior to the first study drug administration
Participants who have medical dietary restrictions
Participants who cannot communicate reliably with the Investigator
Inclusion in a previous group for this clinical study
Intake of an investigational product (IP) within at least 28 days or 5 half-lives; whichever is longer, prior to the first study drug administration
Donation of 50 mL or more of blood in the 28 days prior to the first study drug administration
Donation of 500 mL or more of blood in the 56 days prior to the first study drug administration
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Laval | Quebec | h7v 4bc | Canada |
Not provided
| Label | URL |
|---|---|
| CSR Synopsis | View source |
| Statistical Analysis Plan (SAP) | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Cohort 1: AZD4041 Dose Level 1 | Participants received oral solution of AZD4041 dose level 1 once daily (QD) directly into the mouth using a syringe from Days 1 to 14. |
| FG001 | Cohort 2: AZD4041 Dose Level 2 | Participants received oral solution of AZD4041 dose level 2 QD directly into the mouth using a syringe from Days 1 to 14. |
| FG002 | Cohort 3: AZD4041 Dose Level 3 | Participants received oral solution of AZD4041 dose level 3 QD directly into the mouth using a syringe from Days 1 to 14. |
| FG003 | Cohorts 1-3: Pooled Placebo | Participants received oral solution of placebo equivalent to AZD4041 volume QD directly into the mouth using a syringe from Days 1 to 14. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Safety population included all participants who received at least 1 dose of AZD4041 or placebo.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Cohort 1: AZD4041 Dose Level 1 | Participants received oral solution of AZD4041 dose level 1 QD directly into the mouth using a syringe from Days 1 to 14. |
| BG001 | Cohort 2: AZD4041 Dose Level 2 |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. | Safety population included all participants who received at least 1 dose of AZD4041 or placebo. | Posted | Count of Participants | Participants | From Day 1 to Day 31 |
|
From Day 1 to Day 31
Safety population included all participants who received at least 1 dose of AZD4041 or placebo.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Cohort 1: AZD4041 Dose Level 1 | Participants received oral solution of AZD4041 dose level 1 QD directly into the mouth using a syringe from Days 1 to 14. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Lacrimation increased | Eye disorders | MedDRA 24.1 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Global Clinical Lead | AstraZeneca Clinical study Information Center | +1-877-240-9479 | information.center@astrazeneca.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Feb 3, 2022 | Nov 8, 2023 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | May 12, 2022 | Nov 8, 2023 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D009293 | Opioid-Related Disorders |
| ID | Term |
|---|---|
| D000079524 | Narcotic-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
For each cohort, 9 participants will be randomly assigned to receive AZD4041 and 3 participants will be assigned to receive placebo. Within each cohort, 2 participants will be randomized initially to AZD4041 or placebo (1:1 ratio) to allow a sentinel dosing approach. Providing no clinically significant issues have been noted after the first 3 doses of the initial 2 (sentinel) participants in a cohort and provided the Day 3 safety laboratory tests for the 2 participants have been reviewed, the remaining 10 participants will be randomized to AZD4041 or placebo in an 8:2 ratio. All participants will receive either AZD4041 or placebo administered once daily for 14 days.
Not provided
Not provided
Not provided
| Placebo | Other | Participants will receive oral solution of placebo as stated in arm description. |
|
The C-SSRS is described as a scale developed at Columbia University that has 2-6 questions each in categories of Suicidal Ideation, Intensity of Ideation, Suicidal Behavior, and Actual Attempts. Four constructs were measured. Severity of Suicidal ideation is rated on a 5-point ordinal scale. Intensity of ideation is comprised of 5 items (frequency, duration, controllability, deterrents, and reason for ideation), each rated on a 5-point ordinal scale. Suicidal behavior is rated on a nominal scale that includes actual, aborted, and interrupted attempts; preparatory behavior; and non-suicidal self-injurious behavior. Lethality, assesses actual attempts; actual lethality is rated on a 6-point ordinal scale, and if actual lethality is 0, potential lethality of attempts is rated on a 3-point ordinal scale.The higher the C-SSRS score, the higher the suicide risk (ie. worse outcome).
| Baseline (Days -28 to -1) through Day 17 |
| Number of Participants With Clinically Significant Findings in Physical and Neurological Examinations | Number of participants with clinically significant findings in physical and neurological examinations are reported. | Baseline (Days -28 to -1) through Day 31 |
| Number of Participants With Abnormal Male Hormone Levels as Assessed by the Investigator | Male hormone levels investigated included testosterone, luteinizing hormone, follicle stimulating hormone, and inhibin B. Number of Participants with abnormal male hormone levels as assessed by the investigator are reported. | Day -1, pre-dose and 1.5 hours post-dose on Days 1 and 14 |
The Cmax of AZD4041 after Day 14 dose is reported. |
| Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of AZD4041 After Day 1 Dose | The Tmax of AZD4041 after Day 1 dose is reported. | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of AZD4041 After Day 14 Dose | The Tmax of AZD4041 after Day 14 dose is reported. | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
| Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC0-24) of AZD4041 After Day 1 Dose | The AUC0-24 of AZD4041 after Day 1 dose is reported. | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose |
| Area Under the Concentration-time Curve From Time 0 (Dose Administration) to the Time of Last Quantifiable Concentration (AUC0-t) of AZD4041 After Day 1 Dose | The AUC0-t of AZD4041 after Day 1 dose is reported. | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose |
| Area Under the Concentration-time Curve From Time 0 (Dose Administration) to the Time of Last Quantifiable Concentration (AUC0-t) of AZD4041 After Day 14 Dose | The AUC0-t of AZD4041 after Day 14 dose is reported. | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
| Area Under the Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of AZD4041 After Day 1 Dose | The AUC0-inf of AZD4041 after Day 1 dose is reported. This PK parameter (AUC0-inf) requiring apparent elimination rate constant (λz) estimation was not evaluable for Cohorts 1 and 3 due to meeting either the exclusion criteria R^2 < 0.8 or the extrapolated area > 20%. | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose |
| Area Under the Concentration-time Curve Over the Dosing Interval at Steady State (AUCτ) of AZD4041 After Day 14 Dose | The AUCτ of AZD4041 calculated after Day 14 dose is reported. | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
| Observed Concentration at the End of the Dosing Interval (Ctrough) of AZD4041 | The Ctrough of AZD4041 is reported. | Predose on Days 2 (Day 1, 24-hours), 3, 4, 5, 6, 7, 8, 9, 10, 14 |
| Concentration at the End of the Dosing Interval (Cτ) of AZD4041 After Day 14 Dose | The Cτ of AZD4041 after Day 14 dose is reported. | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
| Terminal Elimination Half-life (t1/2,z) of AZD4041 After Day 1 Dose | The t1/2,z of AZD4041 after Day 1 dose is reported. This PK parameter (t1/2,z) requiring λz estimation was not evaluable for Cohorts 1 and 3 due to meeting either the exclusion criteria R^2 < 0.8 or the extrapolated area > 20%. | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose |
| Terminal Elimination Half-life (t1/2,z) of AZD4041 After Day 14 Dose | The t1/2,z of AZD4041 after Day 14 dose is reported. | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
| Effective Half-life (t1/2Eff) of AZD4041 After Day 14 Dose | The t1/2Eff of AZD4041 after Day 14 dose is reported. | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
| Accumulation Ratio Evaluated by Comparing Day 14 Cmax to Day 1 Cmax (RAC[Cmax]) of AZD4041 | The RAC(Cmax) of AZD4041 is reported. | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose; Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
| Accumulation Ratio Evaluated by Comparing Day 14 AUCτ to Day 1 AUC0-24 (RAC[AUC]) of AZD4041 | The RAC(AUC) of AZD4041 is reported. | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose; Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
| Apparent Total Clearance (CL/F) of AZD4041 After Day 1 Dose | The CL/F of AZD4041 after Day 1 dose is reported. This PK parameter (CL/F) requiring λz estimation was not evaluable for Cohorts 1 and 3 due to meeting either the exclusion criteria R^2 < 0.8 or the extrapolated area > 20%. | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose |
| Apparent Total Clearance at Steady State (CL/Fss) of AZD4041 After Day 14 Dose | The CL/Fss of AZD4041 after Day 14 dose is reported. | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
| Apparent Volume of Distribution (Vz/F) of AZD4041 After Day 1 Dose | The Vz/F of AZD4041 after Day 1 dose is reported. This PK parameter (Vz/F) requiring λz estimation was not evaluable for Cohorts 1 and 3 due to meeting either the exclusion criteria R^2 < 0.8 or the extrapolated area > 20%. | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose |
| Apparent Volume of Distribution at Steady State (Vz/Fss) of AZD4041 After Day 14 Dose | The Vz/Fss of AZD4041 after Day 14 dose is reported. | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
| Apparent Elimination Rate Constant (λZ) of AZD4041 After Day 14 Dose | The λZ of AZD4041 after Day 14 dose is reported. | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
| Amount of AZD4041 Excreted Unchanged in Urine Over the 24-hour Dosing Interval (Ae0-24) After Day 1 Dose | The Ae0-24 of AZD4041 after Day 1 dose is reported. | Day 1: Predose spot collection, and 0 to 6 hours, 6 to 12 hours, and 12 to 24 hours postdose |
| Amount of AZD4041 Excreted Unchanged in Urine Over the 24-hour Dosing Interval (Ae0-24) After Day 14 Dose | The Ae0-24 of AZD4041 after Day 14 dose is reported. | Day 14: Predose spot collection, and 0 to 6 hours, 6 to 12 hours, and 12 to 24 hours postdose |
| Apparent Fraction of AZD4041 Excreted Unchanged in Urine Over the 24-hours Dosing Interval (fe/F0-24) After Day 1 Dose | The fe/F0-24 of AZD4041 after Day 1 dose is reported. | Day 1: Predose spot collection, and 0 to 6 hours, 6 to 12 hours, and 12 to 24 hours postdose |
| Apparent Fraction of AZD4041 Excreted Unchanged in Urine Over the 24-hours Dosing Interval (fe/F0-24) After Day 14 Dose | The fe/F0-24 of AZD4041 after Day 14 dose is reported. | Day 14: Predose spot collection, and 0 to 6 hours, 6 to 12 hours, and 12 to 24 hours postdose |
| Apparent Renal Clearance Over the 24-hours Dosing Interval (CLR 0-24) of AZD4041 After Day 1 Dose | The CLR 0-24 of AZD4041 after Day 1 dose is reported. Apparent renal clearance was calculated as: Ae (0-24) / AUC0-24 on Day 1. | Day 1: Predose spot collection, and 0 to 6 hours, 6 to 12 hours, and 12 to 24 hours postdose |
| Apparent Renal Clearance Over the 24-hours Dosing Interval (CLR 0-24) of AZD4041 After Day 14 Dose | The CLR 0-24 of AZD4041 after Day 14 dose is reported. Apparent renal clearance was calculated as: Ae (0-24) / AUCτ on Day 14. | Day 14: Predose spot collection, and 0 to 6 hours, 6 to 12 hours, and 12 to 24 hours postdose |
| Cerebrospinal Fluid (CSF) Concentration as a Percentage of Total Plasma Concentration of AZD4041 in Cohorts 2 and 3 | The CSF concentration as a percentage of total plasma concentration of AZD4041 in cohorts 2 and 3 is reported. | Day 14 post dose (approximately 3 hours ± 1 hour) |
| CSF Concentration as a Percentage of Free Plasma Concentration of AZD4041 in Cohorts 2 and 3 | The CSF concentration as a percentage of free plasma concentration of AZD4041 in cohorts 2 and 3 is reported. | Day 14 post dose (approximately 3 hours ± 1 hour) |
| Day 14 / Day 1 Ratio of 4-β-hydroxy-cholesterol Concentrations | Day 14 / Day 1 ratio of 4-β-hydroxy-cholesterol concentrations is reported. | Pre-dose Day 1 and 24 hours post Day 14 dose |
| Protocol | View source |
Participants received oral solution of AZD4041 dose level 2 QD directly into the mouth using a syringe from Days 1 to 14.
| BG002 | Cohort 3: AZD4041 Dose Level 3 | Participants received oral solution of AZD4041 dose level 3 QD directly into the mouth using a syringe from Days 1 to 14. |
| BG003 | Cohorts 1-3: Pooled Placebo | Participants received oral solution of placebo equivalent to AZD4041 volume QD directly into the mouth using a syringe from Days 1 to 14. |
| BG004 | Total | Total of all reporting groups |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
Participants received oral solution of AZD4041 dose level 1 QD directly into the mouth using a syringe from Days 1 to 14. |
| OG001 | Cohort 2: AZD4041 Dose Level 2 | Participants received oral solution of AZD4041 dose level 2 QD directly into the mouth using a syringe from Days 1 to 14. |
| OG002 | Cohort 3: AZD4041 Dose Level 3 | Participants received oral solution of AZD4041 dose level 3 QD directly into the mouth using a syringe from Days 1 to 14. |
| OG003 | Cohorts 1-3: Pooled Placebo | Participants received oral solution of placebo equivalent to AZD4041 volume QD directly into the mouth using a syringe from Days 1 to 14. |
|
|
| Primary | Number of Participants With Abnormal Vital Signs Reported as TEAEs | Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal finding in the vital sign parameters (blood pressure, pulse rate, and body temperature). | Safety population included all participants who received at least 1 dose of AZD4041 or placebo. | Posted | Count of Participants | Participants | From Day 1 to Day 31 |
|
|
|
| Primary | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs | Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported. Abnormal clinical laboratory parameters defined as any abnormal finding during analysis of general biochemistry, hematology, and urinalysis. | Safety population included all participants who received at least 1 dose of AZD4041 or placebo. | Posted | Count of Participants | Participants | From Day 1 to Day 31 |
|
|
|
| Primary | Number of Participants With Abnormal Electrocardiograms (ECGs) Reported as TEAEs | Number of participants with abnormal ECGs reported as TEAEs are reported. | Safety population included all participants who received at least 1 dose of AZD4041 or placebo. | Posted | Count of Participants | Participants | From Day 1 to Day 31 |
|
|
|
| Primary | Number of Participants With Suicidal Ideation or Behavior Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) | The C-SSRS is described as a scale developed at Columbia University that has 2-6 questions each in categories of Suicidal Ideation, Intensity of Ideation, Suicidal Behavior, and Actual Attempts. Four constructs were measured. Severity of Suicidal ideation is rated on a 5-point ordinal scale. Intensity of ideation is comprised of 5 items (frequency, duration, controllability, deterrents, and reason for ideation), each rated on a 5-point ordinal scale. Suicidal behavior is rated on a nominal scale that includes actual, aborted, and interrupted attempts; preparatory behavior; and non-suicidal self-injurious behavior. Lethality, assesses actual attempts; actual lethality is rated on a 6-point ordinal scale, and if actual lethality is 0, potential lethality of attempts is rated on a 3-point ordinal scale.The higher the C-SSRS score, the higher the suicide risk (ie. worse outcome). | Safety population included all participants who received at least 1 dose of AZD4041 or placebo. | Posted | Count of Participants | Participants | Baseline (Days -28 to -1) through Day 17 |
|
|
|
| Primary | Number of Participants With Clinically Significant Findings in Physical and Neurological Examinations | Number of participants with clinically significant findings in physical and neurological examinations are reported. | Safety population included all participants who received at least 1 dose of AZD4041 or placebo. | Posted | Count of Participants | Participants | Baseline (Days -28 to -1) through Day 31 |
|
|
|
| Primary | Number of Participants With Abnormal Male Hormone Levels as Assessed by the Investigator | Male hormone levels investigated included testosterone, luteinizing hormone, follicle stimulating hormone, and inhibin B. Number of Participants with abnormal male hormone levels as assessed by the investigator are reported. | Safety population included all participants who received at least 1 dose of AZD4041 or placebo. | Posted | Count of Participants | Participants | Day -1, pre-dose and 1.5 hours post-dose on Days 1 and 14 |
|
|
|
| Secondary | Maximum Observed Plasma Concentration (Cmax) of AZD4041 After Day 1 Dose | The Cmax of AZD4041 after Day 1 dose is reported. | Pharmacokinetic (PK) population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng/mL | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose |
|
|
|
| Secondary | Maximum Observed Plasma Concentration (Cmax) of AZD4041 After Day 14 Dose | The Cmax of AZD4041 after Day 14 dose is reported. | Pharmacokinetic (PK) population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate PK samples and excludes participants with inadequate PK samples due to missed blood draw, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng/mL | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
|
|
|
| Secondary | Time to Reach Maximum Observed Plasma Concentration (Tmax) of AZD4041 After Day 1 Dose | The Tmax of AZD4041 after Day 1 dose is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. | Posted | Median | Full Range | Hour | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose |
|
|
|
| Secondary | Time to Reach Maximum Observed Plasma Concentration (Tmax) of AZD4041 After Day 14 Dose | The Tmax of AZD4041 after Day 14 dose is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate PK samples and excludes participants with inadequate PK samples due to missed blood draw, an AE, meal deviation, or concomitant medication intake. | Posted | Median | Full Range | Hour | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
|
|
|
| Secondary | Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC0-24) of AZD4041 After Day 1 Dose | The AUC0-24 of AZD4041 after Day 1 dose is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. | Posted | Geometric Mean | Geometric Coefficient of Variation | h*ng/mL | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose |
|
|
|
| Secondary | Area Under the Concentration-time Curve From Time 0 (Dose Administration) to the Time of Last Quantifiable Concentration (AUC0-t) of AZD4041 After Day 1 Dose | The AUC0-t of AZD4041 after Day 1 dose is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. | Posted | Geometric Mean | Geometric Coefficient of Variation | h*ng/mL | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose |
|
|
|
| Secondary | Area Under the Concentration-time Curve From Time 0 (Dose Administration) to the Time of Last Quantifiable Concentration (AUC0-t) of AZD4041 After Day 14 Dose | The AUC0-t of AZD4041 after Day 14 dose is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate PK samples and excludes participants with inadequate PK samples due to missed blood draw, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | h*ng/mL | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
|
|
|
| Secondary | Area Under the Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of AZD4041 After Day 1 Dose | The AUC0-inf of AZD4041 after Day 1 dose is reported. This PK parameter (AUC0-inf) requiring apparent elimination rate constant (λz) estimation was not evaluable for Cohorts 1 and 3 due to meeting either the exclusion criteria R^2 < 0.8 or the extrapolated area > 20%. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate PK samples and excludes participants with inadequate PK samples due to missed blood draw, an AE, meal deviation, or concomitant medication intake. | Posted | Median | Full Range | h*ng/mL | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose |
|
|
|
| Secondary | Area Under the Concentration-time Curve Over the Dosing Interval at Steady State (AUCτ) of AZD4041 After Day 14 Dose | The AUCτ of AZD4041 calculated after Day 14 dose is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate PK samples and excludes participants with inadequate PK samples due to missed blood draw, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | h*ng/mL | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
|
|
|
| Secondary | Observed Concentration at the End of the Dosing Interval (Ctrough) of AZD4041 | The Ctrough of AZD4041 is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number analyzed (n) denotes those participants who were analyzed for the specified time points. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng/mL | Predose on Days 2 (Day 1, 24-hours), 3, 4, 5, 6, 7, 8, 9, 10, 14 |
|
|
|
| Secondary | Concentration at the End of the Dosing Interval (Cτ) of AZD4041 After Day 14 Dose | The Cτ of AZD4041 after Day 14 dose is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate PK samples and excludes participants with inadequate PK samples due to missed blood draw, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng/mL | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
|
|
|
| Secondary | Terminal Elimination Half-life (t1/2,z) of AZD4041 After Day 1 Dose | The t1/2,z of AZD4041 after Day 1 dose is reported. This PK parameter (t1/2,z) requiring λz estimation was not evaluable for Cohorts 1 and 3 due to meeting either the exclusion criteria R^2 < 0.8 or the extrapolated area > 20%. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate PK samples and excludes participants with inadequate PK samples due to missed blood draw, an AE, meal deviation, or concomitant medication intake. | Posted | Median | Full Range | hour | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose |
|
|
|
| Secondary | Terminal Elimination Half-life (t1/2,z) of AZD4041 After Day 14 Dose | The t1/2,z of AZD4041 after Day 14 dose is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate PK samples and excludes participants with inadequate PK samples due to missed blood draw, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | Hour | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
|
|
|
| Secondary | Effective Half-life (t1/2Eff) of AZD4041 After Day 14 Dose | The t1/2Eff of AZD4041 after Day 14 dose is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate PK samples and excludes participants with inadequate PK samples due to missed blood draw, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | Hour | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
|
|
|
| Secondary | Accumulation Ratio Evaluated by Comparing Day 14 Cmax to Day 1 Cmax (RAC[Cmax]) of AZD4041 | The RAC(Cmax) of AZD4041 is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate PK samples and excludes participants with inadequate PK samples due to missed blood draw, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | Ratio | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose; Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
|
|
|
| Secondary | Accumulation Ratio Evaluated by Comparing Day 14 AUCτ to Day 1 AUC0-24 (RAC[AUC]) of AZD4041 | The RAC(AUC) of AZD4041 is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate PK samples and excludes participants with inadequate PK samples due to missed blood draw, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | Ratio | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose; Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
|
|
|
| Secondary | Apparent Total Clearance (CL/F) of AZD4041 After Day 1 Dose | The CL/F of AZD4041 after Day 1 dose is reported. This PK parameter (CL/F) requiring λz estimation was not evaluable for Cohorts 1 and 3 due to meeting either the exclusion criteria R^2 < 0.8 or the extrapolated area > 20%. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate PK samples and excludes participants with inadequate PK samples due to missed blood draw, an AE, meal deviation, or concomitant medication intake. | Posted | Median | Full Range | L/hour | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose |
|
|
|
| Secondary | Apparent Total Clearance at Steady State (CL/Fss) of AZD4041 After Day 14 Dose | The CL/Fss of AZD4041 after Day 14 dose is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate PK samples and excludes participants with inadequate PK samples due to missed blood draw, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | L/hour | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
|
|
|
| Secondary | Apparent Volume of Distribution (Vz/F) of AZD4041 After Day 1 Dose | The Vz/F of AZD4041 after Day 1 dose is reported. This PK parameter (Vz/F) requiring λz estimation was not evaluable for Cohorts 1 and 3 due to meeting either the exclusion criteria R^2 < 0.8 or the extrapolated area > 20%. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate PK samples and excludes participants with inadequate PK samples due to missed blood draw, an AE, meal deviation, or concomitant medication intake. | Posted | Median | Full Range | L | Day 1: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose |
|
|
|
| Secondary | Apparent Volume of Distribution at Steady State (Vz/Fss) of AZD4041 After Day 14 Dose | The Vz/Fss of AZD4041 after Day 14 dose is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate PK samples and excludes participants with inadequate PK samples due to missed blood draw, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | L | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
|
|
|
| Secondary | Apparent Elimination Rate Constant (λZ) of AZD4041 After Day 14 Dose | The λZ of AZD4041 after Day 14 dose is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate PK samples and excludes participants with inadequate PK samples due to missed blood draw, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | 1/hour | Day 14: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose |
|
|
|
| Secondary | Amount of AZD4041 Excreted Unchanged in Urine Over the 24-hour Dosing Interval (Ae0-24) After Day 1 Dose | The Ae0-24 of AZD4041 after Day 1 dose is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate urine PK samples and excludes participants with inadequate urine PK samples due to missed urine collection, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng | Day 1: Predose spot collection, and 0 to 6 hours, 6 to 12 hours, and 12 to 24 hours postdose |
|
|
|
| Secondary | Amount of AZD4041 Excreted Unchanged in Urine Over the 24-hour Dosing Interval (Ae0-24) After Day 14 Dose | The Ae0-24 of AZD4041 after Day 14 dose is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate urine PK samples and excludes participants with inadequate urine PK samples due to missed urine collection, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng | Day 14: Predose spot collection, and 0 to 6 hours, 6 to 12 hours, and 12 to 24 hours postdose |
|
|
|
| Secondary | Apparent Fraction of AZD4041 Excreted Unchanged in Urine Over the 24-hours Dosing Interval (fe/F0-24) After Day 1 Dose | The fe/F0-24 of AZD4041 after Day 1 dose is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate urine PK samples and excludes participants with inadequate urine PK samples due to missed urine collection, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | Percentage | Day 1: Predose spot collection, and 0 to 6 hours, 6 to 12 hours, and 12 to 24 hours postdose |
|
|
|
| Secondary | Apparent Fraction of AZD4041 Excreted Unchanged in Urine Over the 24-hours Dosing Interval (fe/F0-24) After Day 14 Dose | The fe/F0-24 of AZD4041 after Day 14 dose is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate urine PK samples and excludes participants with inadequate urine PK samples due to missed urine collection, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | Percentage | Day 14: Predose spot collection, and 0 to 6 hours, 6 to 12 hours, and 12 to 24 hours postdose |
|
|
|
| Secondary | Apparent Renal Clearance Over the 24-hours Dosing Interval (CLR 0-24) of AZD4041 After Day 1 Dose | The CLR 0-24 of AZD4041 after Day 1 dose is reported. Apparent renal clearance was calculated as: Ae (0-24) / AUC0-24 on Day 1. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate urine PK samples and excludes participants with inadequate urine PK samples due to missed urine collection, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | L/hour | Day 1: Predose spot collection, and 0 to 6 hours, 6 to 12 hours, and 12 to 24 hours postdose |
|
|
|
| Secondary | Apparent Renal Clearance Over the 24-hours Dosing Interval (CLR 0-24) of AZD4041 After Day 14 Dose | The CLR 0-24 of AZD4041 after Day 14 dose is reported. Apparent renal clearance was calculated as: Ae (0-24) / AUCτ on Day 14. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate urine PK samples and excludes participants with inadequate urine PK samples due to missed urine collection, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | L/hour | Day 14: Predose spot collection, and 0 to 6 hours, 6 to 12 hours, and 12 to 24 hours postdose |
|
|
|
| Secondary | Cerebrospinal Fluid (CSF) Concentration as a Percentage of Total Plasma Concentration of AZD4041 in Cohorts 2 and 3 | The CSF concentration as a percentage of total plasma concentration of AZD4041 in cohorts 2 and 3 is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate CSF PK samples and excludes participants with inadequate CSF PK samples due to missed CSF draw, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | Percentage | Day 14 post dose (approximately 3 hours ± 1 hour) |
|
|
|
| Secondary | CSF Concentration as a Percentage of Free Plasma Concentration of AZD4041 in Cohorts 2 and 3 | The CSF concentration as a percentage of free plasma concentration of AZD4041 in cohorts 2 and 3 is reported. | The PK population included all participants who had received at least 1 dose of AZD4041 and had at least 1 PK concentration after dosing. Here, number of participants analyzed (N) indicates those participants who had adequate CSF PK samples and excludes participants with inadequate CSF PK samples due to missed CSF draw, an AE, meal deviation, or concomitant medication intake. | Posted | Geometric Mean | Geometric Coefficient of Variation | Percentage | Day 14 post dose (approximately 3 hours ± 1 hour) |
|
|
|
| Secondary | Day 14 / Day 1 Ratio of 4-β-hydroxy-cholesterol Concentrations | Day 14 / Day 1 ratio of 4-β-hydroxy-cholesterol concentrations is reported. | Pharmacodynamic (PD) population included all participants who had received at least 1 dose of AZD4041 or placebo and had at least 1 plasma 4-β-hydroxy-cholesterol concentration after dosing. | Posted | Geometric Mean | Geometric Coefficient of Variation | Ratio | Pre-dose Day 1 and 24 hours post Day 14 dose |
|
|
|
| 0 |
| 9 |
| 0 |
| 9 |
| 8 |
| 9 |
| EG001 | Cohort 2: AZD4041 Dose Level 2 | Participants received oral solution of AZD4041 dose level 2 QD directly into the mouth using a syringe from Days 1 to 14. | 0 | 9 | 0 | 9 | 6 | 9 |
| EG002 | Cohort 3: AZD4041 Dose Level 3 | Participants received oral solution of AZD4041 dose level 3 QD directly into the mouth using a syringe from Days 1 to 14. | 0 | 9 | 0 | 9 | 6 | 9 |
| EG003 | Cohorts 1-3: Pooled Placebo | Participants received oral solution of placebo equivalent to AZD4041 volume QD directly into the mouth using a syringe from Days 1 to 14. | 0 | 9 | 0 | 9 | 9 | 9 |
| Ocular hyperaemia | Eye disorders | MedDRA 24.1 | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Dry mouth | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Lip dry | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Catheter site pain | General disorders | MedDRA 24.1 | Systematic Assessment |
|
| Chest discomfort | General disorders | MedDRA 24.1 | Systematic Assessment |
|
| Fatigue | General disorders | MedDRA 24.1 | Systematic Assessment |
|
| Palpitations | Cardiac disorders | MedDRA 24.1 | Systematic Assessment |
|
| Medical device site reaction | General disorders | MedDRA 24.1 | Systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Post lumbar puncture syndrome | Injury, poisoning and procedural complications | MedDRA 24.1 | Systematic Assessment |
|
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 24.1 | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Muscle spasms | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Tendonitis | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
|
| Dyskinesia | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
|
| Sinus tachycardia | Cardiac disorders | MedDRA 24.1 | Systematic Assessment |
|
| Abnormal dreams | Psychiatric disorders | MedDRA 24.1 | Systematic Assessment |
|
| Insomnia | Psychiatric disorders | MedDRA 24.1 | Systematic Assessment |
|
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Nasal dryness | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Throat irritation | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Acne | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Blister | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Erythema | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Ventricular tachycardia | Cardiac disorders | MedDRA 24.1 | Systematic Assessment |
|
| Ear discomfort | Ear and labyrinth disorders | MedDRA 24.1 | Systematic Assessment |
|
| Hypoacusis | Ear and labyrinth disorders | MedDRA 24.1 | Systematic Assessment |
|
| Tinnitus | Ear and labyrinth disorders | MedDRA 24.1 | Systematic Assessment |
|
| Eye pain | Eye disorders | MedDRA 24.1 | Systematic Assessment |
|
| Eye pruritus | Eye disorders | MedDRA 24.1 | Systematic Assessment |
|
MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.
| Sinus tachycardia |
|
| Suicidal behavior |
|
| Day 3 |
|
|
| Day 4 |
|
|
| Day 5 |
|
|
| Day 6 |
|
|
| Day 7 |
|
|
| Day 8 |
|
|
| Day 9 |
|
|
| Day 10 |
|
|
| Day 14 |
|
|